tradingkey.logo

Cartesian Therapeutics’ Descartes-08 Observed To Provide Deep And Sustained Benefits Through Month 12 After A Single Course Of Therapy In Phase 2B Myasthenia Gravis Trial

ReutersApr 8, 2025 11:04 AM

- Cartesian Therapeutics Inc RNAC.O:

  • CARTESIAN THERAPEUTICS’ DESCARTES-08 OBSERVED TO PROVIDE DEEP AND SUSTAINED BENEFITS THROUGH MONTH 12 AFTER A SINGLE COURSE OF THERAPY IN PHASE 2B MYASTHENIA GRAVIS TRIAL

  • CARTESIAN THERAPEUTICS INC - PHASE 3 AURORA TRIAL ON TRACK TO DOSE FIRST PATIENT IN 2Q25

  • CARTESIAN THERAPEUTICS-SAFETY PROFILE CONSISTENT WITH PREVIOUSLY REPORTED DATA AND CONTINUES TO SUPPORT OUTPATIENT ADMINISTRATION

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI